Tsubota Lab Rebounds on Joint Research with Farstoma on UFB Water Eye Drops

トレーダーズ・ウェブ··JP·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Tsubota Lab announced on the 7th that it has concluded a joint research agreement with Farstoma for the development of eye drops using ultrafine bubble (UFB) water, and its stock price rebounded. Farstoma has been advancing research on applying the characteristics of high-concentration UFB water to drug delivery systems for pharmaceuticals. This time, combining it with Tsubota Lab's expertise in the ophthalmology field, they will verify the applicability of UFB water to eye drops. Based on the findings obtained, they plan to consider the development of new pharmaceuticals in the ophthalmology field.

Impact on assets 1

Aging Population▲
Tsubota Laboratory Incorporated
4890
▲ PositiveTechnologyrelevance

Tsubota Lab signed a joint research agreement with Farstoma to develop UFB-water eye drops, leveraging its ophthalmology expertise.

Off-coverage companies 1

ファルストマ株式会社 (Pharstoma)i
Private▲ PositiveTechnologyrelevance

Farstoma concluded a joint research agreement with Tsubota Lab to verify UFB water applicability for eye drops and new ophthalmology drugs.